Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.

Oncotarget · 2018 · PMC5787470 · PMID 29416618

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, when the cell lines were stratified into GCB and non-GCB subsets, in ixazomib-treated cells the GCB subset showed a trend toward a positive correlation for the c-proteasome subunits and a negative correlation for the i-proteasome subunits, particularly MECL-1 (Figure 3A ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.